ストロメリシンプロモーター5A/6Aポリモルフィズムは,急性心筋梗塞と関連しています
M Terashima1, H Akita, K Kanazawa
1First Department of Internal Medicine, Kobe University School of Medicine, Kobe, and Himeji Cardiovascular Center, Hyogo, Japan.
Circulation
|June 3, 1999
まとめ
ストロメリシン遺伝子プロモーターにおける一般的な遺伝的変異体,5A/6Aポリモルフィズムが,急性心筋梗塞 (AMI) の重要な危険因子である. この発見は,心臓発作に寄与する新しい経路を強調しています.
科学分野:
- 心血管遺伝学 心血管遺伝学
- 分子生物学は分子生物学である.
- 動脈硬化症の病原性について
背景:
- プラーク破裂は,急性心筋梗塞 (AMI) に繋がる重要なイベントです.
- ストロメリシンを含むマトリックス金属タンパク質酵素 (MMPs) は,動脈硬化性プラークキャップの弱まりに関与しています.
- ストロメリシン遺伝子プロモーターに共通する5A/6Aポリモルフィズムが遺伝子転写に影響を与える可能性があります.
研究 の 目的:
- ストロメリシン遺伝子5A/6AポリモルフィズムとAMIのリスクとの関連を調べる.
- この遺伝子変異体が,AMIの独立した危険因子であるかどうかを判断する.
主な方法:
- 330人のAMI患者と330人の対照群でケース・コントロール研究が行われました.
- ストロメリシン遺伝子プロモーターにおける5A/6Aポリモルフィズムに関する遺伝子タイプ化が行われました.
- 関連性を評価するために,物流回帰を含む統計分析が使用されました.
主要な成果:
- 5A/6A+5A/5A遺伝子型は,対照群 (32.7%) と比較して,AMI患者 (48.8%) で有意に多く見られた.
- 5A/6A+5A/5A遺伝子型に関連したAMIの確率比は2.25.でした.
- この関連性は,統計的に有意であり,他の心血管疾患のリスク要因とは無関係でした.
結論:
- ストロメリシン遺伝子プロモーターの5A/6Aポリモルフィズムは,AMIの新たな病原遺伝的危険因子です.
- この遺伝子変異は,急性心筋梗塞の発生と進行に役割を果たす可能性があります.
関連する概念動画
01:21Drugs Affecting Neurotransmitter Release or Uptake
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:30Acute Coronary Syndrome I: Introduction
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
01:25Cardiopulmonary Resuscitation IV: Pharmacological Management
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...